Washington, May 18 (RHC)-- U.S. President Donald Trump has named Moncef Slaoui, a former executive at pGlaxoSmithKline, and Army General Gustave Perna to lead the effort to develop a coronavirus vaccine, which Trump has dubbed “Operation Warp Speed.”
Some observers have raised a red flag over a possible conflict of interest as Slaoui holds $10 million in stock options at biotech company Moderna, Inc., which recently received $480 million in federal funding for coronavirus vaccine trials.
